744251-46-5Relevant academic research and scientific papers
TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
-
Page/Page column 47, (2010/11/30)
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently,
TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
-
Page/Page column 59, (2008/06/13)
The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently,
Macrocyclic hepatitis C serine protease inhibitors
-
Page/Page column 146, (2008/06/13)
The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
